https://scholars.lib.ntu.edu.tw/handle/123456789/454430
標題: | Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy | 作者: | Hsieh M.-C Chang W.-W Yu H.-H Lu C.-Y Chang C.-L Chow J.-M SHEE-UAN CHEN Cheng Y Wu S.-Y. |
關鍵字: | Adjuvant chemotherapy alone; concurrent chemoradiotherapy; pancreatic adenocarcinoma; sequential chemoradiotherapy; survival | 公開日期: | 2018 | 卷: | 7 | 期: | 6 | 起(迄)頁: | 2328-2338 | 來源出版物: | Cancer Medicine | 摘要: | In the era of intensity modulation radiation therapy (IMRT), no prospective randomized trial has evaluated the efficacy of adjuvant therapies such as adjuvant concurrent chemoradiotherapy (CCRT), adjuvant sequential chemotherapy and radiotherapy (CT-RT), and adjuvant CT alone in resectable pancreatic adenocarcinoma (PA). Through propensity score matching, we designed a nationwide, population-based, head-to-head cohort study to determine the effects of dissimilar adjuvant treatments on resectable PA. We minimized the confounding of various adjuvant treatment outcomes among the following resectable PA groups of patients from the Taiwan Cancer Registry database: group 1, adjuvant CCRT; group 2, adjuvant sequential CT-RT; and group 3, adjuvant CT alone. All the studied techniques are IMRTs. The matching process yielded a final cohort of 588 patients (196, 196, and 196 patients in groups 1, 2, and 3, respectively). In both univariate and multivariate Cox regression analyses, adjusted hazard ratios (aHRs; 95% confidence interval [CI]) of death derived for the adjuvant CCRT and adjuvant sequential CT-RT cohorts compared with the adjuvant CT alone cohort were 0.398 (0.314–0.504) and 0.307 (0.235–0.402), respectively. A combination of adjuvant IMRT and CT for resectable PA treatment improves survival to a greater extent than does adjuvant CT alone. ? 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/454430 | ISSN: | 2045-7634 | DOI: | 10.1002/cam4.1479 | SDG/關鍵字: | fluoropyrimidine derivative; gemcitabine; adjuvant chemoradiotherapy; adjuvant chemotherapy; adjuvant radiotherapy; adjuvant therapy; adult; aged; Article; cancer registry; cancer survival; cohort analysis; controlled study; female; human; intensity modulated radiation therapy; major clinical study; male; middle aged; overall survival; pancreas adenocarcinoma; population research; priority journal; propensity score; Taiwan; treatment outcome; adenocarcinoma; adjuvant chemoradiotherapy; intensity modulated radiation therapy; mortality; pancreas tumor; pathology; procedures; survival analysis; Adenocarcinoma; Aged; Chemoradiotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Survival Analysis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。